• Profile
Close

Sotatercept for the treatment of pulmonary arterial hypertension

New England Journal of Medicine Apr 07, 2021

Humbert M, McLaughlin V, Gibbs JSR, et al. - Researchers undertook this 24-week multicenter trial to test sotatercept (a novel fusion protein) as a treatment option for pulmonary arterial hypertension. Participants were 106 adults who were taking background therapy for pulmonary arterial hypertension. These were randomized to receive subcutaneous sotatercept at a dose of 0.3 mg per kilogram of body weight every 3 weeks, 0.7 mg per kilogram every 3 weeks, or placebo. Findings demonstrated that a decrease in pulmonary vascular resistance was conferred by sotatercept in patients receiving background therapy for pulmonary arterial hypertension. Sotatercept was also linked to a decrease in N-terminal pro–B-type natriuretic peptide levels.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay